Checkpoint inhibitors against PD-1, PD-L1, CTLA-4 are dramatically improving cancer treatment in defined patient sub-sets. Combining them together and with chemo seems even more effective, as shown by coming Asco communications from Roche/Genentech and Bristol Myers Squibb Optimizing product portfolio and launch strategy is among BlueJet Consulting areas of expertise. Contact us for a free diagnosis. #postcovid19 #Oncology Continue reading
Comments